A phase I study to evaluate the safety and immunogenicity of recombinant HIV-1 envelope antigen [HIV gp120 vaccine] in children born to HIV-infected mothers

Trial Profile

A phase I study to evaluate the safety and immunogenicity of recombinant HIV-1 envelope antigen [HIV gp120 vaccine] in children born to HIV-infected mothers

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs HIV gp120 vaccine (Primary)
  • Indications HIV infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 28 Sep 2008 Actual initiation date added as 1 Nov 1999 as reported by ClinicalTrials.gov.
    • 28 Sep 2008 Planned end date added as 1 Jun 2005 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top